Optimizing inhaler mouthpiece design - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Optimizing inhaler mouthpiece design


Pharmaceutical Technology Europe
Volume 22, Issue 1


Nasal spray advances
Only around 10–20% of asthma medications are delivered to the lungs because of the barrier-nature of the respiratory tract and medication loss in the inhaler during the inhalation process. Thus, optimizing inhaler design would go some way to reducing waste and improving the reproducibility of drug delivery to the lungs. Through our research,1 using the mouthpiece as an example, we have developed a methodology that allows inhaler design to be optimized. I believe this approach could provide significant advantages compared with traditional inhaler design methods.

Getting the design right

We used a computational and experimental approach to design an optimized mouthpiece for a new prototype inhaler that minimizes the amount of medication lost on the mouthpiece. The analysis process uses in vitro experimental studies of aerosol performance in an initial prototype mouthpiece to validate developed computational fluid dynamic (CFD) methods for the aerosol inhaler. We then use the CFD model to quantitatively analyse the relationship between mouthpiece drug deposition with resulting aerosol transport conditions to identify critical design attributes.

During the design phase, these relationships are used to modify in silico the mouthpiece design to target the desired critical design attributes. The modified design is tested experimentally to verify agreement with the CFD model predicted deposition, and the CFD and in vitro guided design process repeats as needed to achieve the required mouthpiece performance criteria. Performance of the final optimized mouthpiece design should then be verified using in vitro experiments. By minimizing the drug deposition within the mouthpiece we can increase the amount of drug available to the patient for inhalation and increase deposition within the airways.

With our research, we were not looking to develop a generic mouthpiece design; rather we wanted to illustrate a rational design methodology that would be beneficial during any inhaler design process using this combined computation and experimental analysis and design approach.

The future?

An optimized inhaler design could reduce the velocity at which the spray is delivered from the inhaler, thereby reducing impaction deposition on the mouthpiece and the patients' throat. This will improve both drug delivery efficiency and reproducibility.

The next generation of pharmaceuticals to be delivered to and via the respiratory tract may not have the large therapeutic window that is generally seen with today's inhaled drugs. Next generation inhaler designs that improve drug deposition efficiency and reproducibility may, therefore, be required for the next generation systemic drugs delivered via the lungs.

Reference

1. M. Hindle and P.W. Longest, "A quantitative analysis and design (QAD) approach to produce an optimized aerosol spray inhaler mouthpiece," 2009 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition (Los Angeles, CA, USA, 8–12 November 2009).

Professor Hindle's research was presented at the 2009 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, 8–12 November 2009, Los Angeles, CA, USA.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here